Header Logo

Connection

Michael Heneka to Amyloidosis

This is a "connection" page, showing publications Michael Heneka has written about Amyloidosis.
Connection Strength

1.012
  1. Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A, Heneka MT. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int. 2010 Nov; 57(4):375-82.
    View in: PubMed
    Score: 0.317
  2. D?zel E, Ziegler G, Berron D, Maass A, Sch?tze H, Cardenas-Blanco A, Glanz W, Metzger C, Dobisch L, Reuter M, Spottke A, Brosseron F, Fliessbach K, Heneka MT, Laske C, Peters O, Priller J, Spruth EJ, Ramirez A, Speck O, Schneider A, Teipel S, Kilimann I, Jens W, Schott BH, Preis L, Gref D, Maier F, Munk MH, Roy N, Ballarini T, Yakupov R, Haynes JD, Dechent P, Scheffler K, Wagner M, Jessen F. Amyloid pathology but not APOE e4 status is permissive for tau-related hippocampal dysfunction. Brain. 2022 05 24; 145(4):1473-1485.
    View in: PubMed
    Score: 0.186
  3. Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, Aarsland D, Alcolea D, Altomare D, von Arnim C, Baiardi S, Baldeiras I, Barthel H, Bateman RJ, Van Berckel B, Binette AP, Blennow K, Boada M, Boecker H, Bottlaender M, den Braber A, Brooks DJ, Van Buchem MA, Camus V, Carill JM, Cerman J, Chen K, Ch?telat G, Chipi E, Cohen AD, Daniels A, Delarue M, Didic M, Drzezga A, Dubois B, Eckerstr?m M, Ekblad LL, Engelborghs S, Epelbaum S, Fagan AM, Fan Y, Fladby T, Fleisher AS, Van der Flier WM, F?rster S, Fortea J, Frederiksen KS, Freund-Levi Y, Frings L, Frisoni GB, Fr?hlich L, Gabryelewicz T, Gertz HJ, Gill KD, Gkatzima O, G?mez-Tortosa E, Grimmer T, Guedj E, Habeck CG, Hampel H, Handels R, Hansson O, Hausner L, Hellwig S, Heneka MT, Herukka SK, Hildebrandt H, Hodges J, Hort J, Huang CC, Iriondo AJ, Itoh Y, Ivanoiu A, Jagust WJ, Jessen F, Johannsen P, Johnson KA, Kandimalla R, Kapaki EN, Kern S, Kilander L, Klimkowicz-Mrowiec A, Klunk WE, Koglin N, Kornhuber J, Kramberger MG, Kuo HC, Van Laere K, Landau SM, Landeau B, Lee DY, de Leon M, Leyton CE, Lin KJ, Lle? A, L?wenmark M, Madsen K, Maier W, Marcusson J, Marqui? M, Martinez-Lage P, Maserejian N, Mattsson N, de Mendon?a A, Meyer PT, Miller BL, Minatani S, Mintun MA, Mok VCT, Molinuevo JL, Morbelli SD, Morris JC, Mroczko B, Na DL, Newberg A, Nobili F, Nordberg A, Olde Rikkert MGM, de Oliveira CR, Olivieri P, Orellana A, Paraskevas G, Parchi P, Pardini M, Parnetti L, Peters O, Poirier J, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Reiman EM, Rinne JO, Rodrigue KM, Rodr?guez-Rodriguez E, Roe CM, Rosa-Neto P, Rosen HJ, Rot U, Rowe CC, R?ther E, Ruiz A, Sabri O, Sakhardande J, S?nchez-Juan P, Sando SB, Santana I, Sarazin M, Scheltens P, Schr?der J, Selnes P, Seo SW, Silva D, Skoog I, Snyder PJ, Soininen H, Sollberger M, Sperling RA, Spiru L, Stern Y, Stomrud E, Takeda A, Teichmann M, Teunissen CE, Thompson LI, Tomassen J, Tsolaki M, Vandenberghe R, Verbeek MM, Verhey FRJ, Villemagne V, Villeneuve S, Vogelgsang J, Waldemar G, Wallin A, Wallin ?K, Wiltfang J, Wolk DA, Yen TC, Zboch M, Zetterberg H. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurol. 2022 03 01; 79(3):228-243.
    View in: PubMed
    Score: 0.183
  4. Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, Fladby T, Molinuevo JL, Villeneuve S, Hort J, Epelbaum S, Lle? A, Engelborghs S, van der Flier WM, Landau S, Popp J, Wallin A, Scheltens P, Rikkert MO, Snyder PJ, Rowe C, Ch?telat G, Ru?z A, Marqui? M, Chipi E, Wolfsgruber S, Heneka M, Boecker H, Peters O, Jarholm J, Rami L, Tort-Merino A, Binette AP, Poirier J, Rosa-Neto P, Cerman J, Dubois B, Teichmann M, Alcolea D, Fortea J, S?nchez-Saudin?s MB, Ebenau J, Pocnet C, Eckerstr?m M, Thompson L, Villemagne V, Buckley R, Burnham S, Delarue M, Freund-Levi Y, Wallin ?K, Ramakers I, Tsolaki M, Soininen H, Hampel H, Spiru L, Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, Visser PJ. Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimers Dement. 2022 10; 18(10):1832-1845.
    View in: PubMed
    Score: 0.180
  5. Kummer MP, Hermes M, Delekarte A, Hammerschmidt T, Kumar S, Terwel D, Walter J, Pape HC, K?nig S, Roeber S, Jessen F, Klockgether T, Korte M, Heneka MT. Nitration of tyrosine 10 critically enhances amyloid ? aggregation and plaque formation. Neuron. 2011 Sep 08; 71(5):833-44.
    View in: PubMed
    Score: 0.089
  6. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain. 2005 Jun; 128(Pt 6):1442-53.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.